Med Ad NewsThe Pharma Industry Download the PharmaLiveSearch.com toolbar Sure sense of balance: With more than 100 new third-party relationships annually, Johnson & Johnson has completed a string of important acquisitions, experienced more than seven decades of sales increases, and holds leadership positions in ethical and OTC pharmaceuticals, medical/surgical supplies, diagnostics, and consumer products. Johnson Johnson experienced its 72nd year of consecutive sales growth in 2004. Last year marked the completion of two compete decades of consecutive double-digit earnings increases, excluding special charges. The company achieved a strong, balanced performance in 2004, posting record results in sales, earnings, and cash flow. J J s medical-devices business segment will become much larger after the completed acquisition by year-end 2005 of Although the late-stage pipeline looks bare, Johnson Johnson s early-stage pipeline is filling up. Morningstar analysts believe there is a lot of potential in the pipeline and predict that J J will file for 13 new drug approvals between 2005 and 2007. The company has 17 new molecular entities in full development. The company has 70 potential filings between 2005 and 2011, including 23 new molecular entities and 47 line extensions. Of the potential filings, 43 are small molecules, and 27 are biologics. The highest percentage of potential filings is in the oncology category, at 29%. Central nervous system drugs make up 19% of the potential filings, immune-mediated inflammatory disease comprises 17%, infectious disease comprises 10%, pain comprises 7%, anemia comprises 7%, reproductive medicine comprises 6%, cardiovascular comprises 4%, and 1% comes from drugs in other categories.
